 |
|
|
| |
Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Patients with Genotype 1 Hepatitis C: Final Results
|
| |
| |
Phase 2 Study of Telaprevir Administered q8h or q12h with ...
Nov 4, 2008 ... Results of this interim analysis warrant further evaluation of a twice-daily telaprevir dosing regimen in treatment-naïve genotype 1 ...
www.natap.org/2008/AASLD/AASLD_43.htm
Reported by Jules Levin
AASLD Nov 3 2009, Boston, MA
From Jules: the study results are encouraging but perhaps another larger study should be conducted to confirm these results. The discontinuarion rate in this study is lower than in previous studies at least in part due to better rash management, which would have been expected with more long-term use of telaprevir, and this is very encouraging. Also encouraging are the higher SVR rates of 83% compared to 61-69% in the phase 2 studies, which are I think due in part to the better rash management & lower discontinuation rates. SVR rate for patients receiving 24 weeks therapy was higher than those getting 48 weeks therapy.
Patrick Marcellin,1Xavier Forns,2Tobias Goeser,3Peter Ferenci,4Frederik Nevens,5Giampiero Carosi,6Joost P Drenth,7Koen De Backer8Rolf van Heeswijk,8Don Luo,8Gaston Picchio,9Maria Beumont8
1Hopital Beaujon, Clichy, France;2Liver Unit, University of Barcelona, Barcelona, Spain;3Klinikum der Universitat zu Koln, Koln, Germany; 4Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria; 5Department of Hepatology, University Hospital Gasthuisberg, Leuven, Belgium; 6Clinic of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy; 7Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 8Tibotec BVBA, Mechelen, Belgium; 9Tibotec Inc., Yardley, PA, USA
|
| |
|
|
|
|
|
